Adial Pharmaceuticals Inc <Q> expected to post a loss of 49 cents a share - Earnings Preview

Reuters
2025.05.14 20:02
portai
I'm PortAI, I can summarize articles.

Adial Pharmaceuticals Inc is expected to report a loss of 49 cents per share for the quarter ending March 31, 2025, with no change in quarterly revenue. The average analyst rating is "buy," with a median 12-month price target of $6.50, significantly above its last closing price of $0.63. The earnings estimate has remained unchanged over the last three months.

  • Adial Pharmaceuticals Inc ADIL.OQ ADIL.O is expected to show no change in quarterly revenue when it reports results on May 16 (estimated) for the period ending March 31 2025


  • ​LSEG's mean analyst estimate for Adial Pharmaceuticals Inc is for a loss of 49 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Adial Pharmaceuticals Inc is $6.50​, above​ its last closing price of $0.63. ​​​

This summary was machine generated May 14 at 20:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.